Company profile: TCR2 Therapeutics
1.1 - Company Overview
Company description
- Provider of a unique proprietary TRuC™ platform developed by a discovery-stage pharmaceutical company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TCR2 Therapeutics
Theseus Pharmaceuticals
HQ: United States
Website
- Description: Provider of technology-based pharmaceutical offerings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theseus Pharmaceuticals company profile →
Mirati Therapeutics
HQ: Canada
Website
- Description: Provider of novel cancer therapeutics in clinical development and commercialization; product candidates include MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirati Therapeutics company profile →
MabVax Therapeutics
HQ: United States
Website
- Description: Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MabVax Therapeutics company profile →
WntResearch
HQ: Sweden
Website
- Description: Provider of anti-metastatic cancer therapies targeting WNT5A signaling. Pipeline includes Foxy-5, a peptide drug candidate that mimics WNT5A to reduce cancer cell mobility and spread (Phase I; reconstitutes Wnt-5a effects in breast cancer cells), and Box-5, a peptide in preclinical development that antagonizes Wnt-5a.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WntResearch company profile →
FogPharma
HQ: United States
Website
- Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking β-catenin inhibitor (Phase 1/2), β-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FogPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TCR2 Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TCR2 Therapeutics
2.2 - Growth funds investing in similar companies to TCR2 Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TCR2 Therapeutics
4.2 - Public trading comparable groups for TCR2 Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →